Merck announces Molnupiravir reduced risk of death at a planned interim analysis of its Phase 3 trial

Merck announces Molnupiravir reduced risk of death at a planned interim analysis of its Phase 3 trial

Through Day 29, no deaths were reported in patients who received molnupiravir, as compared to 8 deaths in patients who received placebo.
Check the source here –Source, Financial Express.
Change Language